Inactivating Icmt ameliorates K-RAS-induced myeloproliferative disease. - Wikidata - wikimedia - TriplyDB

Inactivating Icmt ameliorates K-RAS-induced myeloproliferative disease.

Inactivating Icmt ameliorates K-RAS-induced myeloproliferative disease.

http://www.wikidata.org/entity/Q36835230

about

Ras history: The saga continues.Alterations in molecular chaperones and eIF2alpha during lung endothelial cell apoptosis Palmitoylation of oncogenic NRAS is essential for leukemogenesis.Isoprenylcysteine carboxylmethyltransferase is critical for malignant transformation and tumor maintenance by all RAS isoforms.An improved isoprenylcysteine carboxylmethyltransferase inhibitor induces cancer cell death and attenuates tumor growth in vivo.Amide-modified prenylcysteine based Icmt inhibitors: Structure-activity relationships, kinetic analysis and cellular characterization Drugging the undruggable RAS: Mission possible?Small-molecule modulation of Ras signaling.A role for Rac3 GTPase in the regulation of autophagy.Inhibition of Ras for cancer treatment: the search continues.Divergent roles of CAAX motif-signaled posttranslational modifications in the regulation and subcellular localization of Ral GTPases.Modelling oncogenic Ras/Raf signalling in the mouse.Targeting oncogenic Ras signaling in hematologic malignancies.Icmt inhibition exerts anti-angiogenic and anti-hyperpermeability activities impeding malignant pleural effusion.Isoprenylcysteine carboxylmethyltransferase deficiency exacerbates KRAS-driven pancreatic neoplasia via Notch suppression.A RAS renaissance: emerging targeted therapies for KRAS-mutated non-small cell lung cancer.Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?Isoprenylcysteine carboxylmethyltransferase regulates mitochondrial respiration and cancer cell metabolism.Control of RhoA methylation by carboxylesterase I Therapeutic strategies for targeting ras proteins.Isoprenyl carboxyl methyltransferase inhibitors: a brief review including recent patents.RHO methylation matters: a role for isoprenylcysteine carboxylmethyltransferase in cell migration and adhesion.Functional oligomerization of the Saccharomyces cerevisiae isoprenylcysteine carboxyl methyltransferase, Ste14p.KRASG12D expression in lung-resident myeloid cells promotes pulmonary LCH-like neoplasm sensitive to statin treatment.Topology of mammalian isoprenylcysteine carboxyl methyltransferase determined in live cells with a fluorescent probe.Targeting isoprenylcysteine methylation ameliorates disease in a mouse model of progeria.PLC-γ and PI3K link cytokines to ERK activation in hematopoietic cells with normal and oncogenic Kras Mutational analysis of the integral membrane methyltransferase isoprenylcysteine carboxyl methyltransferase (ICMT) reveals potential substrate binding sites.Posttranslational Modifications of RAS Proteins.Regulation of NOTCH signaling by RAB7 and RAB8 requires carboxyl methylation by ICMT.Wild-type KRAS inhibits oncogenic KRAS-induced T-ALL in mice.

P2860

Q30404024-7739F2C2-F5DA-4F5C-9188-B2C3067B1626 Q33784115-D19416BA-F996-43DE-A21A-9743CD8D5245 Q33839862-27F29456-BFCC-4822-BEE6-840A2CDB39C5 Q33886255-86DE0F92-7AA5-48CF-A7C4-D847539D25AF Q34028492-BF6CCDE3-A79D-45EE-A870-BEB149CD9111 Q34091952-92A78B07-430C-4AF9-BF84-A7032694DD25 Q35163434-75FBF12F-D887-4C60-BB94-A8A4A03AF7E1 Q35188280-AE6AF733-9EAB-4743-84B0-0CCDCA7B3741 Q35266447-D76DFF9A-F66F-4F00-8763-D3C15718DC30 Q35944601-EC88D57D-24DE-4A2E-A60D-05A51B7EC14A Q36050056-428D94B1-F827-4AC2-9C72-68D6DCA01F2D Q36076132-5A6C755C-9F58-4C4D-8DC8-EA03820AB8B3 Q36352506-E7D93DF5-5F83-4A8F-8631-2A6A9A4EC76C Q37190280-EE8216BB-13E8-4CDF-8BE9-52F3482AE0B1 Q37259201-D3A32D5F-D034-4819-9A7A-2A85D2CAEEB8 Q37724940-CB6175DA-51E2-4CB1-9557-DDE38B8CF839 Q38423044-6C654BA7-4B76-41C8-B8E1-9D11C7C2D79B Q38963320-5C2D1BA7-54AC-408D-B09F-1EC286387B4E Q39154559-644E95F0-0214-43B1-B01F-D2AAC7EFD46B Q39262217-C0EF7818-1635-4A0D-913A-B85E1FC25247 Q39384869-67B9C70B-979D-4DD5-8892-491CF916C276 Q39662737-286B2D0F-EFA5-4E61-8C6E-EA141FB2F71F Q40186514-DA512D58-6937-4EF4-A9A4-C75FF957FD9C Q41456624-7EDB7051-5B87-421C-A54C-5D31AD4FB7C9 Q41910665-3C4A2A10-50EF-4BCA-9930-11295F0BA306 Q42278285-47A4014B-E844-4DA8-8A38-14D9487B3522 Q42760471-55C4D15D-3649-4B21-BAD3-15441FB9719E Q42790115-FEBFAA21-C856-4132-9273-3B677A824826 Q47223139-0CB28668-DF88-4EEB-B664-4444DA3019A4 Q47626655-84842A60-0122-40D7-AAA8-5FE55E5C784D Q54186255-758A749A-DA76-4C88-A3D5-8E7A42EAA3E0

P2860

Inactivating Icmt ameliorates K-RAS-induced myeloproliferative disease.

http://www.wikidata.org/entity/Q36835230

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Inactivating Icmt ameliorates K-RAS-induced myeloproliferative disease.

@en

type

label

Inactivating Icmt ameliorates K-RAS-induced myeloproliferative disease.

@en

prefLabel

Inactivating Icmt ameliorates K-RAS-induced myeloproliferative disease.

@en

P1433

Q36835230-66AD1EC0-B43E-490F-ADA8-B7B92DCC6859

P1476

Q36835230-6814D224-B349-462A-90CC-02A7A01A5F2F

P2093

Q36835230-305CE0CB-EC8E-4BCE-B6E3-8EEA58C16B79

Q36835230-6ACA2947-87DF-4E86-A529-4BA1F73DB09F

Q36835230-84F72822-A40A-4A2C-B5C3-074C0E9A853F

Q36835230-85CA4084-DB1E-4BB4-9074-F27C3DA658AB

Q36835230-9BB7A743-959D-4D7F-A47F-A62A66B3A821

Q36835230-A7BC75C1-44A3-478E-9DB2-0208811D8354

P2860

Q36835230-163DA4E6-14C5-41D9-B20C-8406FDE0D1F2

Q36835230-2575C59B-8EE4-4424-A236-B1A8186CFD27

Q36835230-3946444B-835D-4FBE-9D24-1837ED5274C4

Q36835230-3A710C57-D5D1-4BC3-A8FC-F1532B2B9662

Q36835230-3B7C0111-0039-42B4-96A5-306F4FC12AA3

Q36835230-3BB98082-0500-42EF-8872-F265DAA8B44F

Q36835230-44348970-A304-45DF-AB5F-0BB9929F18AF

Q36835230-511B00B2-791C-4672-B9BE-D3D1290E554A

Q36835230-56CAEF5C-AEEE-4BC8-A1F8-D0D8B7EB2BD9

Q36835230-5DCFC97B-927D-4584-BA38-5A678BC37584

P304

Q36835230-7D1C1AD0-64C3-4A2B-A858-AE00FBB89BD0

P31

Q36835230-5AAC06A4-5936-49D5-87A4-448780FEBE91

P356

Q36835230-2B2D5509-845F-4A0A-8372-C3C11F02D144

P407

Q36835230-967B81D3-9FE0-4E0E-8526-10F6DE2089DE

P433

Q36835230-571E1D2E-CBF8-4CC1-A9AE-53F0B91E7F9E

P478

Q36835230-9DC4842F-7FCF-4153-8D1C-011EB278D684

P50

Q36835230-34EBC5AE-8FF6-4D72-9A73-671109770C8E

Q36835230-4902A28F-791A-4E86-8FC1-25F886BEB611

Q36835230-AC1EC5BE-9D8D-4336-88E2-FCAC142E9292

P577

Q36835230-72132E5A-7A14-4447-B9C4-E0AB3B2BC874

P5875

Q36835230-F11928F7-D6D1-458F-90E1-01FE8734A9D6

P698

Q36835230-51621887-ED25-4416-847D-7140C526D2E4

P932

Q36835230-906397F4-8D7F-407D-92CF-257E80E2871D

P356

BLOOD-2007-06-094060

P1433

P1476

Inactivating Icmt ameliorates K-RAS-induced myeloproliferative disease

@en

P2093

Anna-Karin M Sjogren

http://www.w3.org/2001/XMLSchema#string

Annika Lindskog

http://www.w3.org/2001/XMLSchema#string

Annika M Wahlstrom

http://www.w3.org/2001/XMLSchema#string

Briony A Cutts

http://www.w3.org/2001/XMLSchema#string

Christin Karlsson

http://www.w3.org/2001/XMLSchema#string

Martin O Bergo

http://www.w3.org/2001/XMLSchema#string

P2860

Isoprenylcysteine carboxyl methyltransferase deficiency in mice

The role of FLT3 in haematopoietic malignancies

Inactivation of Icmt inhibits transformation by oncogenic K-Ras and B-Raf

In vitro and in vivo effects of a farnesyltransferase inhibitor on Nf1-deficient hematopoietic cells

ras oncogenes in human cancer: a review

Inducible gene targeting in mice

BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein.

Amide-substituted farnesylcysteine analogs as inhibitors of human isoprenylcysteine carboxyl methyltransferase.

Postprenylation CAAX processing is required for proper localization of Ras but not Rho GTPases

A small-molecule inhibitor of isoprenylcysteine carboxyl methyltransferase with antitumor activity in cancer cells.

P304

1357-1365

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2007-06-094060

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

112

http://www.w3.org/2001/XMLSchema#string

P50

Karin M Andersson

Stephen G. Young

P577

2008-05-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5347122

http://www.w3.org/2001/XMLSchema#string

P698

18502828

http://www.w3.org/2001/XMLSchema#string

P932

2515151

http://www.w3.org/2001/XMLSchema#string